Literature DB >> 13138867

Pyrazinamide-isoniazid in tuberculosis.

W McDERMOTT, L ORMOND, C MUSCHENHEIM, K DEUSCHLE, R M McCUNE, R TOMPSETT.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID ISOMERS/therapeutic use; NICOTINIC ACID/derivatives; TUBERCULOSIS/therapy

Mesh：

Substances：

Year:  1954        PMID： 13138867     DOI： 10.1164/art.1954.69.3.319

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  22 in total

1.  DRUGS and liver disease.

Authors: 
Journal:  Br Med J       Date:  1958-11-08

2.  Current methods in the treatment of tuberculosis.

Authors:  J B AMBERSON
Journal:  Bull N Y Acad Med       Date:  1955-01

3.  Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.

Authors:  Tarjinder Sahota; Oscar Della Pasqua
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

4.  Liver and pancreatic injury induced by antituberculous therapy.

Authors:  M Markov; K Patel; A Raeesy; A Bant; D H Van Thiel; A Nadir
Journal:  Dig Dis Sci       Date:  2007-02-15       Impact factor: 3.199

5.  The role of the host in the chemotherapy of tuberculosis.

Authors:  P D HART
Journal:  Br Med J       Date:  1954-10-02

6.  Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 7.  Philip Ellman lecture. The modern management and therapy of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Proc R Soc Med       Date:  1977-01

8.  Concentrations of pyrazinamide attained in serum with different doses of the drug.

Authors:  S Subbammal; D V Krishnamurthy; S P Tripathy; P Venkataraman
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

Review 9.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 10.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.